Pipeline Information

  • HOME
  • Pipeline Information
Product Pipeline-thinking each of youProduct Pipeline-thinking each of you

"Brightening the future of people facing challenges of cancers."
Solasia has been developing a wide range of products varying from pharmaceuticals for cancer therapy to supportive care for adverse event of drugs.

Development Status

PRODUCTS

PIPELINES INDICATION AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

Sancuso®(SP-01)

MORE INFO
Chemotherapy Induced Nausea and Vomiting (CINV) China
Launched in 2019

Solasia sales force:

Beijing, Shanghai, Guangzhou

 

Lee’s Pharma:
China Mainland w/o above 3 cities, Hong Kong and Macau



episil® oral liquid(SP-03)

MORE INFO
Pain associated oral mucositis [Medical Device] Japan
Launched in 2018

Meiji Seika Pharma:

Japan

 

Solasia sales force:

Beijing, Shanghai, Guangzhou

 

Lee’s Pharma:
China Mainland w/o above 3 cities

 

Synex
South Korea

China
Launched in 2019
South Korea
Launched in 2020

PIPELINES

PIPELINES TARGET
INDICATION
AREA PRE-
CLINICAL
CLINIAL STUDY NDA APPROVAL
/LAUNCH
PROGRESS PARTNER
PHASE 1 PHASE 2 PHASE 3

SP-02

MORE INFO
Peripheral T-Cell Lymphoma (PTCL) Japan
Submitted NDA

Nippon Kayaku:
Japan


HB Human BioScience:
Latin America

South Korea, Taiwan, Hong Kong
Pivotal PII study completion, preparation for NDA filing
China
Phase II/III, preparation
US
Phase IIA, completion
EU
Phase II/III, preparation

SP-04

MORE INFO
Chemotherapy Induced Peripheral Neuropathy (CIPN) Japan etc.
Pre-clinical study in taxane-induced peripheral neuropathy

Maruho:
Japan

SP-05

MORE INFO
Colorectal Cancer (CRC) Japan
Global Phase III study

New Pipeline Candidates

RECQL1-siRNA Project

Nucleic acid drug candidate for peritoneal metastases (disseminated metastases developing in the peritoneum): Option agreement for in-license of worldwide rights with GeneCare Research Institute Co., Ltd.

RNA Editing Technology Project

New drug candidates for rare disease and/or oncology based on RNA editing technology utilizing pentatricopeptide repeat (PPR) protein platform technology: Joint R&D agreement with EditForce Inc.

PAGE TOP